Nurix Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated May 20, 2024, reports on the results of Nurix Therapeutics, Inc.'s 2024 Annual Meeting of Stockholders held virtually on that date. The meeting addressed governance matters including director elections, auditor ratification, and executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
There were 39,059,365 shares present, representing approximately 79.46% of voting power. All three proposals were approved:
- Proposal 1 (Election of Directors): Julia P. Gregory and David L. Lacey, M.D. were elected to three-year terms. Gregory received 29,941,782 votes for, while Lacey received 27,120,017 votes for.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of PricewaterhouseCoopers LLP for the fiscal year ending November 30, 2024, with 39,033,254 votes for.
- Proposal 3 (Executive Compensation): The compensation of named executive officers was approved on a non-binding advisory basis with 30,364,001 votes for.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the specific terms of the three-year director terms for Julia P. Gregory and David L. Lacey, M.D.
- Confirm the appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending November 30, 2024.
- Review the definitive proxy statement filed on March 27, 2024, for detailed executive compensation data referenced in Proposal 3.
- Check subsequent filings for the company's financial performance, as this 8-K contains no financial metrics.